We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




CT Algorithm Diagnoses Clear-Cell Renal Cell Carcinoma in Small Solid Masses

By HospiMedica International staff writers
Posted on 30 Jun 2022

A 5-tiered CT scoring algorithm may represent a clinically useful tool for diagnosis of clear-cell renal cell carcinoma (RCC) in small solid renal masses. More...

Researchers at The Ottawa Hospital (Ontario, Canada) conducted a study that included 148 patients (mean age, 58 years; 73 men, 75 women) with 148 small (≤4 cm) solid (>25% enhancing tissue) renal masses that underwent renal-mass CT (unenhanced, corticomedullary, and nephrographic phases) before resection between January 2016 and December 2019. Two radiologists independently evaluated the CT examinations and recorded calcification, mass attenuation in all phases, mass-to-cortex corticomedullary attenuation ratio, and heterogeneity score (5-point Likert scale, assessed in corticomedullary phase).

The study revealed that the 5-tiered CT scoring algorithm - including mass-to-cortex corticomedullary attenuation ratio and heterogeneity score - had substantial interobserver agreement (weighted kappa=0.71) and achieved AUC for diagnosing clear-cell RCC of 0.75 (95% CI, 0.68-0.82) for reader 1 and 0.72 (95% CI, 0.66-0.82) for reader 2.

“A 5-tiered renal CT algorithm, including mass-to-cortex corticomedullary attenuation ratio and heterogeneity score, had substantial inter-observer agreement, moderate AUC and PPV, and high NPV for diagnosing clear-cell RCC,” concluded Nicola Schieda from the department of medical imaging at Canada’s Ottawa Hospital.

“If validated,” the researchers acknowledged, “the CT algorithm may represent a useful clinical tool for diagnosing clear-cell renal cell carcinoma."

Related Links:
The Ottawa Hospital


Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
Blood Gas Analyzer
i-Check200
Pediatric Mask
Respire SOFT
Syringe Pump
SP50 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image Credit: MedUni Wien/Houdek

New Surgical Technique Enlarges Aortic Root for Larger Valve Implantation

When replacing a diseased aortic valve, a small aortic root can prevent surgeons from implanting a prosthesis large enough for the patient’s body size. This can lead to patient-prosthesis mismatch, causing... Read more

Patient Care

view channel
Image Credit: Adobe Stock

AI Platform Personalizes Support Between Visits for Cancer Survivors

Cancer survivors often manage persistent side effects after treatment, including fatigue, anxiety, uncertainty, symptoms, stress, and questions between appointments. Clinical teams need ways to maintain... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: The proposed acquisition would add NeoCast, an investigational next-generation liquid embolic technology for chronic subdural hematoma (cSDH), to Terumo Neuro’s neurovascular portfolio. (Photo courtesy of Arsenal Medical)

Terumo Neuro Acquisition Advances Liquid Embolic Technology for Chronic Subdural Hematoma

Terumo Neuro (Aliso Viejo, CA, USA) signed an agreement to acquire Arsenal Medical Inc. (Waltham, MA, USA), a privately held, clinical-stage biomaterials company. The proposed acquisition would add NeoCast,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.